# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001737287-24-000033
Filing Date
2024-04-23
Accepted
2024-04-23 16:32:34
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | allo-20240423xdefa14axnoti.htm | DEFA14A | 12437
2 |  | allogenetherapeuticsinc_vx.jpg | GRAPHIC | 3783103
3 |  | allogenetherapeuticsinc_vxa.jpg | GRAPHIC | 4330028
| Complete submission text file | 0001737287-24-000033.txt |  | 11171591

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38693 | Film No.: 24865263
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)